GSK2656157 NEW
| Price | $32 | $51 | $74 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: GSK2656157 | CAS No.: 1337532-29-2 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | GSK2656157 |
| Description | GSK2656157 is a highly specific and ATP-competitive PERK inhibitor (IC50: 0.9 nM) in a cell-free assay. The selectivty is 500-fold higher against a panel of 300 kinases. |
| Cell Research | Antiproliferative activity of GSK2656157 against multiple human tumor cell lines as well as primary human microvascular endothelial cells is evaluated in a 3-day proliferation assay using standard culture medium. In the absence of exogeneous UPR inducers, GSK2656157 has no significant effect on the growth of any of these cells with IC50 range of 6–25 mM. (Only for Reference) |
| Kinase Assay | Kinase assay: Inhibitory potency of GSK2656157 is measured using recombinant GST-PERK (536–1116 amino acids) with 6-His-full-length human eIF2a as a substrate. Kinase selectivity is evaluated using 27 kinases at GSK as well as a panel of 300 kinases. |
| In vitro | GSK2656157 inhibits the growth of various human xenograft tumors in mice. Administered at a dose of 50 mg/kg orally, GSK2656157 completely suppresses phospho-PERK Thr980 after 8 hours. Furthermore, with dosages of 50/150 mg/kg administered twice daily, GSK2656157 exhibits a dose-dependent suppression of tumor growth in four different mouse cancer models, achieving a 54-114% inhibition of tumor growth at 150 mg/kg. |
| In vivo | GSK2656157 (1 mM) can induce the unfolded protein response (UPR) and inhibit de novo protein synthesis. It downregulates 6% of UPR-related genes (PPP1R15A, HERPUD1, DDIT3, C/EBP-β, and ERN1), with a reduction exceeding fourfold for these targets. Pre-treatment with GSK2656157 inhibits PERK activation and decreases downstream substrates, including phospho-eIF2a, ATF4, and CHOP (IC50: 10-30 nM). In the absence of exogenous UPR inducers, GSK2656157 does not affect cell growth (IC50: 6-25 mM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 30 mg/mL (72 mM) |
| Keywords | PERK | PKR-like endoplasmic reticulum kinase | Autophagy | GSK 2656157 | Protein kinase R-like endoplasmic reticulum kinase | Inhibitor | GSK-2656157 | Apoptosis | inhibit | GSK2656157 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Curcumin | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Reprogramming Compound Library | Bioactive Compound Library | Endoplasmic Reticulum Stress Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Oxidation-Reduction Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-13 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY